Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update

Clinical Pharmacokinetics, Jun 2019

Massimo Carlo Mauri, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Giovanna Cirnigliaro, Isabel Valli, Alfredo Carlo Altamura

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.1007%2Fs40262-019-00797-7.pdf

Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update

Clinical Pharmacokinetics pp 1–2 | Cite as Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update AuthorsAuthors and affiliations Massimo Carlo MauriSilvia PalettaChiara Di PaceAlessandra ReggioriGiovanna CirnigliaroIsabel ValliAlfredo Carlo Altamura Correction First Online: 19 June 2019 90 Downloads The original article can be found online at  https://doi.org/10.1007/s40262-018-0664-3. 1 Correction to: Clin Pharmacokinet (2018) 57:1493–1528  https://doi.org/10.1007/s40262-018-0664-3 Page 1517, Section 16.1, para 1, lines 1–3 which previously read: The pharmacokinetics of CRP was tested in small short-term studies in both healthy volunteers and in subjects with schizophrenia, with similar results [242]. Should read: The pharmacokinetics of CRP was tested in small short-term studies in healthy volunteers [235] and also in subjects with schizophrenia [242], with similar results. Page 1517, Section 16.1, para 1, lines 4–6 which previously read: Cariprazine is rapidly absorbed, reaching peak concentrations between 3 and 4 h after oral dosing in healthy subjects. Should read: Cariprazine reached peak plasma concentrations between 3 and 4 h after oral dosing in healthy subjects. Page 1517, Section 16.1, para 2, lines 1–5 which previously read: Its pharmacokinetics were linear in terms of AUC but maximum concentrations were more than proportional within the dose range from 3 to 5 mg in healthy subjects. Mean half-life was 2–5 days (1.5–12.5 mg/day) in the subjects with schizophrenia [242]. Should read: Its pharmacokinetics were linear in terms of AUC but maximum concentrations were more than proportional within the single dose range from 0.5 to 2.5 mg in healthy subjects. Mean half-life was 2–5 days (1.5–12.5 mg/day) in the subjects with schizophrenia [235]. Page 1518, Section 16.1, para 2, lines 8–11 which previously read: Additionally, the mean concentrations of DCRP and DDCRP were approximately 30 and 40% in the patients, respectively, of CRP concentrations by the end of 12 weeks of treatment [242]. Should read: Additionally, the mean concentrations of DCRP and DDCRP were approximately 30 and 400% in the patients, respectively, of CRP concentrations by the end of 12 weeks of treatment [242]. Page 1518, Table 8, column 1, row 2, which previously read: Actavis 2015 [243] Should read: Actavis 2015 [242] Page 1518, Table 8, column 2, row 2, which previously read: 6 Should read: 8 Page 1518, Table 8, column 6, row 3, which previously read: 32–49 Should read: 10–22.7 Copyright information © Springer Nature Switzerland AG 2019 Authors and Affiliations Massimo Carlo Mauri1Email authorSilvia Paletta1Chiara Di Pace1Alessandra Reggiori1Giovanna Cirnigliaro1Isabel Valli2Alfredo Carlo Altamura11.Clinical Psychopharmacology Unit, Department of Neuroscience and Mental Health, Clinical PsychiatryFondazione IRCCS Ca’ GrandaMilanItaly2.Department of Psychosis StudiesKing’s College LondonLondonUK


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1007%2Fs40262-019-00797-7.pdf

Massimo Carlo Mauri, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Giovanna Cirnigliaro, Isabel Valli, Alfredo Carlo Altamura. Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update, Clinical Pharmacokinetics, 2019, 1-2, DOI: 10.1007/s40262-019-00797-7